Full Breakdown
Thermostable Hantavirus Vaccine Accelerated After Cruise Ship Outbreak
5/13/2026, 8:59:00 PM
Outbreak on MV Hondius
In May 2026, the Dutch-flagged cruise ship MV Hondius reported an outbreak of the Andes strain of hantavirus near the Canary Islands. WHO confirmed eleven cases, nine laboratory-confirmed, and three deaths among passengers. The source remains unknown and no secondary transmission has been detected.
Vaccine Development and Technology
Researchers at the University of Bath, led by chemist Asel Sartbaeva and her spin-out Ensilitech, are adapting an mRNA vaccine originally targeting the Hantaan strain. The product uses Ensilication®, a silica coating that stabilises the RNA, allowing storage at 2-8 °C and potentially at room temperature, removing the ultra-cold chain needed for most mRNA vaccines. Development is funded by a 2024 UK contract and the Small Business Research Initiative.
Public Health Impact
A thermostable hantavirus vaccine would enable rapid distribution to remote or low-resource regions lacking reliable refrigeration, potentially protecting populations in Southeast Asia, Africa and South America—areas most affected by rodent-borne disease. The technology also tests silica-based stabilisation for other vaccines.
Official Statements
WHO Director-General Tedros Adhanom Ghebreyesus said all suspected and confirmed cases have been isolated under strict medical supervision, minimizing spread. The UK Health Security Agency continues to monitor the situation and advise travelers. The 2024 UK contract underscores a priority to develop vaccines stable without ultra-cold storage.
Challenges and Uncertainties
The antigen was created for Hantaan disease and has not yet been tested against the Andes strain responsible for the cruise outbreak, leaving its efficacy against current cases uncertain.
Conflicting Reports
WHO reports eleven cases (nine confirmed) and three deaths, while other sources cite eight cases (three confirmed, five suspected). The outbreak’s origin remains unidentified.
Verbatim Quotes
- “It's a completely new antigen and … it shows very good immunogenicity against hantaan diseases and we're hoping that this will be, a good antigen to use to produce, a future hantaan virus, vaccine,” — Asel Sartbaeva, chemist, University of Bath, co-founder and CEO of Ensilitech
- “We don't know whether the antigen which we have developed will be useful against Andes (strain) at the moment. We're hoping that it will be, but obviously, until we have actually tested against the Andes virus, we will not know,” — Asel Sartbaeva
- “All suspected and confirmed cases have been isolated and managed under strict medical supervision, minimizing any risk of further transmission.” — Dr Tedros Adhanom Ghebreyesus, WHO Director-General
- “The message is clear: preventing diseases is a lot cheaper than treating them,” — Asel Sartbaeva
Next Steps
The University of Bath will start Phase 1 human trials later in 2026 to assess safety and immune response. Positive results could lead to larger studies and broader use of the silica-based stabilisation platform.
